Christine Dierks

Summary

Affiliation: University Hospital
Country: Germany

Publications

  1. ncbi GDC-0449--targeting the hedgehog signaling pathway
    Christine Dierks
    Department of Hematology and Oncology, Freiburg University Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany
    Recent Results Cancer Res 184:235-8. 2010
  2. ncbi Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation
    Christine Dierks
    Department of Hematology Oncology, University of Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany
    Cancer Cell 14:238-49. 2008
  3. ncbi The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease
    Christine Dierks
    Hematology Oncology, University of Freiburg, Freiburg, Germany
    Cancer Res 70:6193-204. 2010
  4. ncbi Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
    Maike Buchner
    Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
    Blood 115:4497-506. 2010
  5. ncbi Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL
    Sarah Decker
    Department of Hematology Oncology, University Medical Center Freiburg, Hugstetter Strasse 55, Freiburg, Germany
    Blood 119:997-1007. 2012
  6. ncbi The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies
    Maike Buchner
    Department of Haematology and Oncology, University Medical Centre Freiburg, Freiburg, Germany
    Br J Haematol 151:167-78. 2010
  7. ncbi Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia
    Maike Buchner
    University Medical Center Freiburg, Department of Hematology and Oncology, Germany
    Cancer Res 69:5424-32. 2009

Collaborators

Detail Information

Publications7

  1. ncbi GDC-0449--targeting the hedgehog signaling pathway
    Christine Dierks
    Department of Hematology and Oncology, Freiburg University Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany
    Recent Results Cancer Res 184:235-8. 2010
    ..It was successfully tested in a phase-I clinical trial demonstrating good pharmacodynamic (PD) and pharmacokinetic (PK) properties and showing objective response and clinical benefit in several patients with basal cell carcinoma...
  2. ncbi Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation
    Christine Dierks
    Department of Hematology Oncology, University of Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany
    Cancer Cell 14:238-49. 2008
    ..Pharmacological Smo inhibition reduced LSCs in vivo and enhanced time to relapse after end of treatment. Our results indicate that Smo inhibition might be an effective treatment strategy to reduce the LSC pool in CML...
  3. ncbi The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease
    Christine Dierks
    Hematology Oncology, University of Freiburg, Freiburg, Germany
    Cancer Res 70:6193-204. 2010
    ..Therefore, pharmacologic inhibition of SYK in patients with U-PTCLs carrying the ITK-SYK fusion protein might be an effective treatment strategy...
  4. ncbi Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
    Maike Buchner
    Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
    Blood 115:4497-506. 2010
    ..SYK blockade in CLL is a promising therapeutic principle not only for its inhibition of the BCR signaling pathway, but also by inhibiting protective stroma signals in a manner entirely independent of BCR signaling...
  5. ncbi Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL
    Sarah Decker
    Department of Hematology Oncology, University Medical Center Freiburg, Hugstetter Strasse 55, Freiburg, Germany
    Blood 119:997-1007. 2012
    ....
  6. ncbi The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies
    Maike Buchner
    Department of Haematology and Oncology, University Medical Centre Freiburg, Freiburg, Germany
    Br J Haematol 151:167-78. 2010
    ..Our data identify the combination of CXCR4 antagonists with passive - but not active - immunotherapy as a promising potential treatment concept in CLL...
  7. ncbi Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia
    Maike Buchner
    University Medical Center Freiburg, Department of Hematology and Oncology, Germany
    Cancer Res 69:5424-32. 2009
    ..Combination of SYK inhibitors with fludarabine might be a novel treatment option particularly for CLL patients with poor prognosis and should be further evaluated in clinical trials...